A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer

Cell

Volumn 162, Issue 1, 2015, Pages 146-159

  Dietlein, Felix ^a,b   Kalb, Bastian ^a,b   Jokic, Mladen ^a,b   Noll, Elisa M ^c,d   Strong, Alexander ^e   Tharun, Lars ^a   Ozretić, Luka ^a   Künstlinger, Helen ^a   Kambartel, Kato ^a,f   Randerath, Winfried J ^a,g   Jüngst, Christian ^b   Schmitt, Anna ^a,b   Torgovnick, Alessandro ^a,b   Richters, André ^h   Rauh, Daniel ^h   Siedek, Florian ^a   Persigehl, Thorsten ^a   Mauch, Cornelia ^a   Bartkova, Jirina ^i,j,k   Bradley, Allan ^e   Sprick, Martin R ^d   Trumpp, Andreas ^c,d   Rad, Roland ^l   Saur, Dieter ^l   Bartek, Jiri ^i,j,k   Wolf, Jürgen ^a   Büttner, Reinhard ^a   Thomas, Roman K ^a,m   Reinhardt, H Christian ^a,b   more..

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d Heidelberg Institute for Stem Cell Technology and Eexperimental Medicine   (Germany)

^e WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^f Krankenhaus Bethanien   (Germany)

^g Krankenhaus Bethanien Solingen   (Germany)

^h TU DORTMUND UNIVERSITY   (Germany)

ⁱ DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^j PALACKÝ UNIVERSITY   (Czech Republic)

^k KAROLINSKA INSTITUTE   (Sweden)

^l TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^m UNIVERSITY OF COLOGNE   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA AMINO N [5,6 DIHYDRO 2 (1 METHYL 1H PYRAZOL 4 YL) 6 OXO 1H PYRROLO[4,3,2 EF][2,3]BENZODIAZEPIN 8 YL]CYCLOHEXANEACETAMIDE; B RAF KINASE; CHECKPOINT KINASE 1; CISPLATIN; K RAS PROTEIN; MK2 PROTEIN; OLAPARIB; PF 3644022; PROTEIN; PROTEIN SERINE THREONINE KINASE INHIBITOR; RABUSERTIB; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; ENZYME INHIBITOR; KRAS PROTEIN, HUMAN; MAP-KINASE-ACTIVATED KINASE 2; ONCOPROTEIN; PROTEIN KINASE; PROTEIN SERINE THREONINE KINASE; RAS PROTEIN; SIGNAL PEPTIDE;

3T3 CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER RECURRENCE; CANCER SIZE; CARCINOGENESIS; CELL CYCLE CHECKPOINT; CELL CYCLE PHASE; CELL DEATH; CELL ISOLATION; CELL SURVIVAL; CELL VIABILITY; COLON ADENOCARCINOMA; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DRUG EXPOSURE; ENZYME ACTIVITY; ENZYME INHIBITION; GENE REPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LUNG ADENOCARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; MUTATION RATE; NONHUMAN; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REPRODUCIBILITY; SMALL CELL LUNG CANCER; TUMOR XENOGRAFT; ADENOCARCINOMA; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER TRANSPLANTATION; DISEASE MODEL; DRUG EFFECTS; DRUG POTENTIATION; LUNG NEOPLASMS; METABOLISM; TUMOR CELL CULTURE; XENOGRAFT;

MURINAE;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE CHECKPOINTS; DISEASE MODELS, ANIMAL; DNA DAMAGE; DRUG SYNERGISM; ENZYME INHIBITORS; HETEROGRAFTS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MICE; NEOPLASM TRANSPLANTATION; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; TUMOR CELLS, CULTURED;

EID: 84934299233     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2015.05.053     Document Type: Article

References (16)

1. J. Barretina, G. Caponigro, N. Stransky, K. Venkatesan, A.A. Margolin, S. Kim, C.J. Wilson, J. Lehár, G.V. Kryukov, and D. Sonkin The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity Nature 483 2012 603 607
2. J. Bartkova, N. Rezaei, M. Liontos, P. Karakaidos, D. Kletsas, N. Issaeva, L.V. Vassiliou, E. Kolettas, K. Niforou, and V.C. Zoumpourlis Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints Nature 444 2006 633 637
3. A.V. Biankin, N. Waddell, K.S. Kassahn, M.C. Gingras, L.B. Muthuswamy, A.L. Johns, D.K. Miller, P.J. Wilson, A.M. Patch, J. Wu Australian Pancreatic Cancer Genome Initiative Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes Nature 491 2012 399 405
4. Cancer Genome Atlas Research Network Comprehensive molecular profiling of lung adenocarcinoma Nature 511 2014 543 550
5. M. Castedo, J.L. Perfettini, T. Roumier, K. Andreau, R. Medema, and G. Kroemer Cell death by mitotic catastrophe: a molecular definition Oncogene 23 2004 2825 2837
6. N.J. Curtin DNA repair dysregulation from cancer driver to therapeutic target Nat. Rev. Cancer 12 2012 801 817
7. F. Dietlein, L. Thelen, M. Jokic, R.D. Jachimowicz, L. Ivan, G. Knittel, U. Leeser, J. van Oers, W. Edelmann, L.C. Heukamp, and H.C. Reinhardt A functional cancer genomics screen identifies a druggable synthetic lethal interaction between MSH3 and PRKDC Cancer Discov. 4 2014 592 605
8. M. DuPage, A.L. Dooley, and T. Jacks Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase Nat. Protoc. 4 2009 1064 1072
9. S.P. Jackson, and J. Bartek The DNA-damage response in human biology and disease Nature 461 2009 1071 1078
10. D.G. Kirsch, D.M. Dinulescu, J.B. Miller, J. Grimm, P.M. Santiago, N.P. Young, G.P. Nielsen, B.J. Quade, C.J. Chaber, and C.P. Schultz A spatially and temporally restricted mouse model of soft tissue sarcoma Nat. Med. 13 2007 992 997
11. J. Lehár, A.S. Krueger, W. Avery, A.M. Heilbut, L.M. Johansen, E.R. Price, R.J. Rickles, G.F. Short 3rd, J.E. Staunton, and X. Jin Synergistic drug combinations tend to improve therapeutically relevant selectivity Nat. Biotechnol. 27 2009 659 666
12. S. Loewe The problem of synergism and antagonism of combined drugs Arzneimittelforschung 3 1953 285 290
13. R. Rad, J. Cadiñanos, L. Rad, I. Varela, A. Strong, L. Kriegl, F. Constantino-Casas, S. Eser, M. Hieber, and B. Seidler A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention Cancer Cell 24 2013 15 29
14. H.C. Reinhardt, and M.B. Yaffe Phospho-Ser/Thr-binding domains: navigating the cell cycle and DNA damage response Nat. Rev. Mol. Cell Biol. 14 2013 563 580
15. H.C. Reinhardt, P. Hasskamp, I. Schmedding, S. Morandell, M.A.T.M. van Vugt, X. Wang, R. Linding, S.-E. Ong, D. Weaver, S.A. Carr, and M.B. Yaffe DNA damage activates a spatially distinct late cytoplasmic cell-cycle checkpoint network controlled by MK2-mediated RNA stabilization Mol. Cell 40 2010 34 49
16. L. Vermeulen, M. Todaro, F. de Sousa Mello, M.R. Sprick, K. Kemper, M. Perez Alea, D.J. Richel, G. Stassi, and J.P. Medema Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity Proc. Natl. Acad. Sci. USA 105 2008 13427 13432